A DNA alkylating agent
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lurbinectedin

Item No. 44852

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(1′R,6R,6aR,7R,13S,14S,16R)-5-(acetyloxy)-2′,3′,4′,6,6a,7,9′,13,14,16-decahydro-8,14-dihydroxy-6′,9-dimethoxy-4,10,23-trimethyl-spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′-[1H]pyrido[3,4-b]indol]-19-one
CAS Number
497871-47-3
Synonyms
  • PM01183
Molecular Formula
C41H44N4O10S
Formula Weight
784.9
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Acetonitrile:Water (1:1): Slightly Soluble: 0.1-1 mg/mlChloroform: Sparingly Soluble: 1-10 mg/ml
SMILES
CC1=C(OCO2)C2=C([C@H](CO3)N([C@@H](O)[C@H]4N(C)[C@@H]5C6=C(C=C(C)C(OC)=C6O)C4)[C@@]5([H])[C@@H]7SC[C@]8(NCCC9=C8NC%10=CC=C(OC)C=C9%10)C3=O)C7=C1OC(C)=O
InChi Code
InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
InChi Key
YDDMIZRDDREKEP-HWTBNCOESA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $475

    Add

    5 mg

    $1,306

    Add

    10 mg

    $2,375

    Add

    25 mg

    $4,750

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Lurbinectedin is a DNA alkylating agent.1 It induces DNA double-strand breaks (DSBs), cell cycle arrest at the S phase, and apoptosis in A549 lung cancer cells. Lurbinectedin is cytotoxic against a panel of 24 cancer cell lines with a mean GI50 value of 2.7 nM. It increases the levels of cyclic GMP-AMP (cGAMP) synthase (cGAS) and phosphorylated STING, TANK-binding kinase 1 (TBK1), and IFN regulatory factor 3 (IRF3) in PB115, DMS 114, NCI H446, and NCI H196 lung cancer cells when used at a concentration of 10 nM.2 Lurbinectedin (0.18 mg/kg) decreases tumor weight in NCI H460 lung, A2780 ovarian, HT-29 colon, and HGC-27 gastric cancer mouse xenograft models.1 It also decreases tumor volume when used in combination with an antibody targeting programmed cell death 1 ligand 1 (PD-L1) in an immunocompetent genetically engineered mouse model of small cell lung cancer (SCLC).2 Formulations containing lurbinectedin have been used in the treatment of metastatic SCLC.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Leal, J.F., Martínez-Díez, M., García-Hernández, V., et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br. J. Pharmacol. 161(5), 1099-1100 (2010).

    2. Chakraborty, S., Sen, U., Ventura, K., et al. Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell Rep. Med. 5(12), 101852 (2024).